CN110997675B - 新的取代的黄嘌呤衍生物 - Google Patents

新的取代的黄嘌呤衍生物 Download PDF

Info

Publication number
CN110997675B
CN110997675B CN201880045961.0A CN201880045961A CN110997675B CN 110997675 B CN110997675 B CN 110997675B CN 201880045961 A CN201880045961 A CN 201880045961A CN 110997675 B CN110997675 B CN 110997675B
Authority
CN
China
Prior art keywords
disorder
compound
disorders
disease
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880045961.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997675A (zh
Inventor
K·格拉赫
C·艾克迈尔
A·绍尔
S·尤斯特
B·L·谢纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Original Assignee
Hyderabad Bioscience Co ltd
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyderabad Bioscience Co ltd, Boehringer Ingelheim International GmbH filed Critical Hyderabad Bioscience Co ltd
Publication of CN110997675A publication Critical patent/CN110997675A/zh
Application granted granted Critical
Publication of CN110997675B publication Critical patent/CN110997675B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880045961.0A 2017-07-11 2018-07-06 新的取代的黄嘌呤衍生物 Active CN110997675B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
EP17180721.7 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (2)

Publication Number Publication Date
CN110997675A CN110997675A (zh) 2020-04-10
CN110997675B true CN110997675B (zh) 2022-06-07

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045961.0A Active CN110997675B (zh) 2017-07-11 2018-07-06 新的取代的黄嘌呤衍生物

Country Status (32)

Country Link
US (1) US10329292B2 (enExample)
EP (1) EP3652176B1 (enExample)
JP (1) JP7114702B2 (enExample)
KR (1) KR102714554B1 (enExample)
CN (1) CN110997675B (enExample)
AR (1) AR112448A1 (enExample)
AU (1) AU2018299824B2 (enExample)
CA (1) CA3066922A1 (enExample)
CL (1) CL2020000056A1 (enExample)
CO (1) CO2019015102A2 (enExample)
CY (1) CY1125014T1 (enExample)
DK (1) DK3652176T3 (enExample)
EA (1) EA039526B1 (enExample)
ES (1) ES2903268T3 (enExample)
HR (1) HRP20220029T1 (enExample)
HU (1) HUE057600T2 (enExample)
IL (1) IL271799B (enExample)
LT (1) LT3652176T (enExample)
MX (1) MX394089B (enExample)
MY (1) MY200797A (enExample)
PE (1) PE20200861A1 (enExample)
PH (1) PH12020500079A1 (enExample)
PL (1) PL3652176T3 (enExample)
PT (1) PT3652176T (enExample)
RS (1) RS62826B1 (enExample)
SA (1) SA519410851B1 (enExample)
SG (1) SG11201912168TA (enExample)
SI (1) SI3652176T1 (enExample)
SM (1) SMT202200013T1 (enExample)
TW (1) TWI801398B (enExample)
UA (1) UA124793C2 (enExample)
WO (1) WO2019011802A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093084A1 (en) * 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP7408662B2 (ja) * 2018-12-12 2024-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンタン誘導体
JP7502299B2 (ja) * 2018-12-12 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キサンチン誘導体
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506172A (zh) * 2006-07-14 2009-08-12 辉瑞产品公司 （7S）-7-[（5-氟-2-甲基-苄基）氧基]-2-[（2R）-2-甲基哌嗪-1-基]-6，7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐
WO2014143799A2 (en) * 2013-03-15 2014-09-18 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016023830A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506172A (zh) * 2006-07-14 2009-08-12 辉瑞产品公司 （7S）-7-[（5-氟-2-甲基-苄基）氧基]-2-[（2R）-2-甲基哌嗪-1-基]-6，7-二氢-5H-环戊烷并[b]吡啶的酒石酸盐
WO2014143799A2 (en) * 2013-03-15 2014-09-18 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
DK3652176T3 (da) 2022-01-17
SG11201912168TA (en) 2020-01-30
IL271799B (en) 2022-08-01
RS62826B1 (sr) 2022-02-28
IL271799A (en) 2020-02-27
PT3652176T (pt) 2022-01-13
JP2020526591A (ja) 2020-08-31
HUE057600T2 (hu) 2022-05-28
EP3652176B1 (en) 2021-12-15
PL3652176T3 (pl) 2022-04-04
EP3652176A1 (en) 2020-05-20
AU2018299824B2 (en) 2022-06-16
LT3652176T (lt) 2022-02-25
PE20200861A1 (es) 2020-08-25
CL2020000056A1 (es) 2020-06-12
ES2903268T3 (es) 2022-03-31
MY200797A (en) 2024-01-16
PH12020500079A1 (en) 2020-10-05
MX394089B (es) 2025-03-24
AU2018299824A1 (en) 2019-12-19
WO2019011802A1 (en) 2019-01-17
SA519410851B1 (ar) 2023-02-26
HRP20220029T1 (hr) 2022-04-15
CO2019015102A2 (es) 2020-05-15
KR20200030048A (ko) 2020-03-19
CY1125014T1 (el) 2023-03-24
BR112019025611A2 (pt) 2020-06-16
SI3652176T1 (sl) 2022-04-29
EA039526B1 (ru) 2022-02-07
CA3066922A1 (en) 2019-01-17
US20190016722A1 (en) 2019-01-17
NZ759728A (en) 2024-11-29
TWI801398B (zh) 2023-05-11
SMT202200013T1 (it) 2022-03-21
AR112448A1 (es) 2019-10-30
EA202090270A1 (ru) 2020-04-24
TW201908318A (zh) 2019-03-01
MX2020000402A (es) 2020-08-17
UA124793C2 (uk) 2021-11-17
US10329292B2 (en) 2019-06-25
KR102714554B1 (ko) 2024-10-10
JP7114702B2 (ja) 2022-08-08
CN110997675A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
CN110997675B (zh) 新的取代的黄嘌呤衍生物
AU2014317157C1 (en) 1,2,4-triazolo(4,3-a)pyridine compounds and their use as positive allosteric modulators of mGluR2 receptors
CN113166151B (zh) 经取代的黄嘌呤衍生物
JP7408662B2 (ja) 置換キサンタン誘導体
JP6667092B2 (ja) ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
HK40025200B (en) Substituted xanthine derivatives
HK40025200A (en) Substituted xanthine derivatives
CA3119229C (en) Substituted xanthine derivatives
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
CN118715227A (zh) 大环嘧啶衍生物、其制备方法以及含有其作为活性成分的用于预防或治疗神经退行性疾病的药物组合物
EA043969B1 (ru) Замещенные ксантиновые производные

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant